Trial Profile
Efficacy of dasatinib and nilotinib as second-line therapy in patients with chronic myeloid leukemia: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 06 Dec 2016 Results assessing safety and long term survival presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Sep 2016 New trial record